FIELD: medicine.
SUBSTANCE: group of inventions deals with BCG-based immunobiological medication of treating urinary bladder cancer, which additionally contains enzyme or enzymes with provision of cleavage of secretion of urinary bladder mucosa membrane and buffer, taken in therapeutically effective ratio. Group of inventions also deals with method for application of immunobiological medication for treating urinary bladder cancer, consisting in introduction of said immunobiological medication into urinary bladder.
EFFECT: increased efficiency of BCG penetration into cells of urinary bladder mucous layer.
14 cl, 9 ex, 5 dwg, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| INTERFERON BETA IMMUNOBIOLOGICAL AGENT FOR BLADDER CANCER THERAPY AND METHOD FOR USING SAME | 2014 |
|
RU2568575C1 |
| IMMUNOBIOLOGICAL AGENT FOR TREATING URINARY BLADDER CANCER AND METHOD OF APPLICATION THEREOF | 2013 |
|
RU2555327C2 |
| METHOD OF INHIBITING PD-1/PD-L1 SIGNALING PATHWAY IN BLADDER CANCER CELLS | 2023 |
|
RU2812805C1 |
| IMMUNOBIOLOGICAL AGENT AND METHOD FOR USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST EBOLA VIRUS | 2015 |
|
RU2578159C1 |
| METHOD OF PREPARING VACCINE BCG "IMURON" FOR BLADDER CANCER IMMUNOTHERAPY | 1999 |
|
RU2170103C1 |
| URINARY BLADDER CANCER TREATMENT METHOD | 2004 |
|
RU2257912C1 |
| ABX196 FOR USE IN TREATMENT OF BLADDER CANCER | 2018 |
|
RU2778812C2 |
| METHOD FOR INCREASING ANTITUMOUR RESISTANCE, ANTIOXIDANT AND IMMUNOSTIMULATING EFFECTS ON THE BODY | 2019 |
|
RU2755638C2 |
| METHOD FOR TREATING POSTOPERATIONAL PURULENT-INFLAMMATORY COMPLICATIONS INDUCED BY CROSS INFECTION | 2003 |
|
RU2246273C2 |
| METHOD FOR COMBINED TREATMENT OF NON-MUSCLE-INVASIVE BLADDER CANCER T1-T2 N0+M0 | 2022 |
|
RU2787917C1 |
